Therapeutics

BriaCell Therapeutics (BCTX) priced a public offering of 5.37M units, with each unit consisting of one common share and one warrant. Each unit is being sold to the public at…

Investor Insight Cardiol Therapeutics is positioned with a late-stage lead asset, multiple orphan indications, strong clinical proof-of-concept data, and a differentiated non-immunosuppressive approach to inflammatory heart disease. The company’s 2025–2026…